Paul Tudor Jones Verona Pharma PLC Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Verona Pharma PLC stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 31,100 shares of VRNA stock, worth $3.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
31,100
Previous 88,324
64.79%
Holding current value
$3.32 Million
Previous $5.61 Million
47.55%
% of portfolio
0.01%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
310Shares Held
75.5MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$656 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$589 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$441 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$326 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...